Name | (S)-N-cyclopentyl-N-[3-[(2,2-dimethyl-1-oxopropyl)thio]-2-methyl-1-oxopropyl]glycine |
---|---|
Synonyms |
Pivalopril
Pivopril |
Description | Pivalopril is a new orally active angiotensin converting enzyme (ACE) inhibitor. |
---|---|
Related Catalog | |
Target |
ACE[1] |
In Vivo | Pivalopril is a new compound with a hindered sulfur group that has been compared to Captopril for oral angiotensin-converting enzyme (ACE) inhibition in rats and dogs and antihypertensive activity in rats. In separate groups of conscious normotensive rats, Pivalopril (0.03-1.0 mg/kg, orally [p.o.]) produces a dose-related antagonism of angiotensin I (AngI)-induced pressor effects. The ED50 for Pivalopril and Captopril is 0.1 mg/kg. In conscious normotensive dogs, Pivalopril (incremental doses of 0.01-1.0 mg/kg, p.o.) produces a dose-related antagonism of AngI pressor effects. The ED50 is 0.17 mg/kg for Pivalopril and 0.06 mg/kg for Captopril. At equieffective doses the two compounds have similar durations of action. In sodium-deficient, conscious spontaneously hypertensive rats (SHR), Pivalopril (1-100 mg/kg, p.o.) produces a dose-related reduction in mean arterial pressure. The potency and duration are similar to those of Captopril. In the sodium-replete SHR, 5 days of oral dosing with Pivalopril (100 mg/kg per day) decreases mean arterial pressure more effectively than Captopril (100 mg/kg per day). It is concluded that Pivalopril is a potent, orally effective ACE inhibitor and antihypertensive agent[2]. |
References |
Density | 1.16g/cm3 |
---|---|
Boiling Point | 490.431°C at 760 mmHg |
Molecular Formula | C16H27NO4S |
Molecular Weight | 329.45500 |
Flash Point | 250.4±26.8 °C |
Exact Mass | 329.16600 |
PSA | 99.98000 |
LogP | 2.78420 |
Vapour Pressure | 0.0±2.7 mmHg at 25°C |
Index of Refraction | 1.531 |
Storage condition | 2-8℃ |